The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 6, 2004, Pages 310-314

  Hermanns, Norbert ^a,b   Burkert, A ^a   Haak, T ^a  

^a FIDAM   (Germany)

^b FIDAM   (Germany)

Author keywords

Acarbose; Combination therapy; Insulin lispro; Postprandial blood glucose; Type 2 diabetes

Indexed keywords

ACARBOSE; C PEPTIDE; GLUCOSE; INSULIN LISPRO; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MIXTURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MEAL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOOD; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLACEBOS; TRIGLYCERIDES;

EID: 3042725656     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-820908     Document Type: Article

References (28)

1. American College of Endocrinology. Consensus statement on guidelines r glycemic control. Endocr Pract 2002; 8 (Suppl 1): 5-11
2. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24: 775-778
3. Anderson Jr JH, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1249-1255
4. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998; 21: 1236-1239
5. Bland M. An Introduction to Medical Statistics. 3rd. ed. Oxford: Oxford University Press, 2000
6. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125-132
7. Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121: 928-935
8. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring Type II diabetes. Diabetes Care 1995; 18: 928-932
9. DECODE Study Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-404
10. Duckworth WC. Hyperglycemia and cardiovascular disease. Curr Atheroscler Rep 2001; 3: 383-391
11. European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabetic Medicine 1999; 16: 716-730
12. Frank M, Köglmeier J, Sneige N, Alawi H. Effect of acarbose on the need for between-meal snacking in patients with Type 1 diabetes: a placebo-controlled, double-blind, cross-over study. Diabetes Nutr Metab 1998; 11: 169-174
13. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocrine Reviews 1998; 19: 583-592
14. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, The DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583
15. Hanefeld M. Post-prandial hyperglycaemia and vascular disease. Int J Clin Pract 2000; (Suppl 112): 13-18
16. Herman ME, Moore RS. The importance of postprandial glucose to treatments and outcomes in patients with Type 2 diabetes. Manag Care Interface 2001; 14: 63-69
17. Holman RR, Turner RC. Practical guide to basal and prandial insulin therapy. Diabetic Medicine 1985; 2: 45-53
18. Holman RR, Turner RC, Cull CA. A randomised double blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years (U. K. Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-964
19. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402
20. Kawamori R. Asymptomatic hyperglycaemia and early atheriosclerotic changes. Diabetes Res Clin Pract 1998; 40 (Suppl): S35-S42
21. Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J. Efficacy and safety of acarbose in insulin-treated patients with Type 2 diabetes. Diabetes Care 1998; 21: 2056-2061
22. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Review 1998; 6: 132-145
23. Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204
24. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999; 57: 19-29
25. Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001; 24: 292-298
26. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-1834
27. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, Bolli GB. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lsy(B28),Pro(B29)] in IDDM. Diabetologia 1994; 37: 713-720
28. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853